A TGFbeta-responsive Gene Signature is Associated with a Subset of Diffuse Scleroderma with Increased Disease Severity

Overview

Journal J Invest Dermatol

Publisher Elsevier

Specialty Dermatology

Date 2009 Oct 9

PMID 19812599

Citations 81

Authors

Jennifer L Sargent

Ausra Milano

Swati Bhattacharyya

John Varga

M Kari Connolly

Howard Y Chang

Michael L Whitfield

Affiliations

Soon will be listed here.

Abstract

Systemic sclerosis is a complex disease with widespread skin fibrosis and variable visceral organ involvement. Since transforming growth factor-beta (TGFbeta) has been implicated in driving fibrosis in systemic sclerosis, a mechanism-derived gene expression signature was used to assay TGFbeta-responsive gene expression in the skin of patients with systemic sclerosis (SSc). Primary dermal fibroblasts from patients with diffuse SSc (dSSc) and healthy controls were treated with TGFbeta, and the genome-wide gene expression was measured on DNA microarrays over a time course of 24 hours. Eight hundred and ninety-four probes representing 674 uniquely annotated genes were identified as TGFbeta responsive. Expression of the TGFbeta-responsive signature was examined in skin biopsies from 17 dSSc, seven limited SSc (lSSc), three morphea patients, and six healthy controls. The TGFbeta-responsive signature was expressed in 10 out of 17 dSSc skin biopsies, but was not found in lSSc, morphea, or healthy control biopsies. Expression of dSSC the TGFbeta-responsive signature stratifies patients into two major groups, one of which corresponds to the "diffuse-proliferation" intrinsic subset that showed higher modified Rodnan skin score and a higher likelihood of scleroderma lung disease. The TGFbeta-responsive signature is found in only a subset of dSSc patients who could be targeted by specific therapies.

Citing Articles

Noncanonical WNT5A controls the activation of latent TGF-β to drive fibroblast activation and tissue fibrosis.

Trinh-Minh T, Chen C, Tran Manh C, Li Y, Zhu H, Zhou X J Clin Invest. 2024; 134(10).

PMID: 38747285 PMC: 11093613. DOI: 10.1172/JCI159884.

Pharmacological inhibition of TAK1 prevents and induces regression of experimental organ fibrosis.

Bale S, Verma P, Yalavarthi B, Scarneo S, Hughes P, Amin M JCI Insight. 2023; 8(14).

PMID: 37306632 PMC: 10443806. DOI: 10.1172/jci.insight.165358.

Extracellular matrix stiffness-The central cue for skin fibrosis.

Wang K, Wen D, Xu X, Zhao R, Jiang F, Yuan S Front Mol Biosci. 2023; 10:1132353.

PMID: 36968277 PMC: 10031116. DOI: 10.3389/fmolb.2023.1132353.

Collagen V α1 Chain Decrease in Papillary Dermis from Early Systemic Sclerosis: A New Proposal in Cutaneous Fibrosis Molecular Structure.

de Morais J, Velosa A, Andrade P, Frediani D, Carrasco S, Queiroz Z Int J Mol Sci. 2022; 23(20).

PMID: 36293511 PMC: 9604101. DOI: 10.3390/ijms232012654.

A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosis.

Franks J, Toledo D, Martyanov V, Wang Y, Huang S, Wood T Rheumatology (Oxford). 2022; 62(1):19-28.

PMID: 35751592 PMC: 9788818. DOI: 10.1093/rheumatology/keac344.

References

Varga J . Antifibrotic therapy in scleroderma: extracellular or intracellular targeting of activated fibroblasts?. Curr Rheumatol Rep. 2004; 6(2):164-70. DOI: 10.1007/s11926-004-0062-8. View

Barnett A, Miller M, Littlejohn G . The diagnosis and classification of scleroderma (systemic sclerosis). Postgrad Med J. 1988; 64(748):121-5. PMC: 2428791. DOI: 10.1136/pgmj.64.748.121. View

Segal E, Shapira M, Regev A, Peer D, Botstein D, Koller D . Module networks: identifying regulatory modules and their condition-specific regulators from gene expression data. Nat Genet. 2003; 34(2):166-76. DOI: 10.1038/ng1165. View

Leask A . Transcriptional profiling of the scleroderma fibroblast reveals a potential role for connective tissue growth factor (CTGF) in pathological fibrosis. Keio J Med. 2004; 53(2):74-7. DOI: 10.2302/kjm.53.74. View

Barnett A, Miller M, Littlejohn G . A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol. 1988; 15(2):276-83. View

Gabrielli A, Di Loreto C, Taborro R, Candela M, Sambo P, Nitti C . Immunohistochemical localization of intracellular and extracellular associated TGF beta in the skin of patients with systemic sclerosis (scleroderma) and primary Raynaud's phenomenon. Clin Immunol Immunopathol. 1993; 68(3):340-9. DOI: 10.1006/clin.1993.1136. View

Daniels C, Wilkes M, Edens M, Kottom T, Murphy S, Limper A . Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest. 2004; 114(9):1308-16. PMC: 524221. DOI: 10.1172/JCI19603. View

Mummery C . Transforming growth factor beta and mouse development. Microsc Res Tech. 2001; 52(4):374-86. DOI: 10.1002/1097-0029(20010215)52:4<374::AID-JEMT1022>3.0.CO;2-8. View

Kuroda K, Shinkai H . Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res. 1997; 289(10):567-72. DOI: 10.1007/s004030050241. View

10.

Kubo M, Ihn H, Yamane K, Tamaki K . Upregulated expression of transforming growth factor-beta receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis. J Rheumatol. 2002; 29(12):2558-64. View

11.

Jinnin M, Ihn H, Mimura Y, Asano Y, Tamaki K . Potential regulatory elements of the constitutive up-regulated alpha2(I) collagen gene in scleroderma dermal fibroblasts. Biochem Biophys Res Commun. 2006; 343(3):904-9. DOI: 10.1016/j.bbrc.2006.03.037. View

12.

Gardner H, Shearstone J, Bandaru R, Crowell T, Lynes M, Trojanowska M . Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum. 2006; 54(6):1961-73. DOI: 10.1002/art.21894. View

13.

Chang H, Chi J, Dudoit S, Bondre C, van de Rijn M, Botstein D . Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci U S A. 2002; 99(20):12877-82. PMC: 130553. DOI: 10.1073/pnas.162488599. View

14.

Svegliati Baroni S, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M . Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med. 2006; 354(25):2667-76. DOI: 10.1056/NEJMoa052955. View

15.

LeRoy E, Black C, FLEISCHMAJER R, Jablonska S, Krieg T, Medsger Jr T . Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988; 15(2):202-5. View

16.

Varga J, Whitfield M . Transforming growth factor-beta in systemic sclerosis (scleroderma). Front Biosci (Schol Ed). 2009; 1(1):226-35. DOI: 10.2741/s22. View

17.

Xu W, LeRoy E, Smith E . Fibronectin release by systemic sclerosis and normal dermal fibroblasts in response to TGF-beta. J Rheumatol. 1991; 18(2):241-6. View

18.

Classen J, Henrohn D, Rorsman F, Lennartsson J, Lauwerys B, Wikstrom G . Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis. Arthritis Rheum. 2009; 60(4):1137-44. DOI: 10.1002/art.24381. View

19.

Wall N, Hogan B . TGF-beta related genes in development. Curr Opin Genet Dev. 1994; 4(4):517-22. DOI: 10.1016/0959-437x(94)90066-c. View

20.

Whitfield M, Finlay D, Murray J, Troyanskaya O, Chi J, Pergamenschikov A . Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A. 2003; 100(21):12319-24. PMC: 218756. DOI: 10.1073/pnas.1635114100. View